“Sending out Integration Test Email #1 (It passed btw) might be the best marketing that @hbomax has ever done,†wrote another
Shares of Orphazyme A/S undefined plummeted 54.3% in premarket trading Friday, after the Denmark-based biopharmaceutical company said overnight that it received a "Complete Response Letter" (CRL) from the U.SThe company said its guidance range for operating losses has widened to DKK670 million to DKK700 million ($107.4 million to $112.2 million) from DKK100 million to DKK150 million)
Orphazyme's stock made the rounds in social media last week, after the stock skyrocketed as much as 1,387% intraday on June 10 before closing up 301.5% in very volatile trading, even as the company said it was not aware of any reason for the "extreme volatility" in its share price